In a large clinical trial, vorasidenib slowed the growth of low-grade gliomas that had mutations in the IDH1 or IDH2 genes. Vorasidenib is the first targeted drug developed specifically to treat brain tumors.
Giving the drug blinatumomab (Blincyto) after standard chemotherapy greatly increased survival for infants with an aggressive form of acute lymphoblastic leukemia (ALL), a recent clinical trial showed. If confirmed in larger studies, the treatment may become standard therapy for infants with ALL caused by KMT2A rearrangements.
To help women in rural areas get up-to-date cancer screenings for breast, cervical, and colorectal cancers, researchers conducted a trial in which they sent them tailored videos and scheduled follow-up calls with patient navigators.
NCI launched a large precision medicine cancer initiative to test the effectiveness of treating adults and children with new drug combinations that target specific genetic changes in the tumor. Known as the Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH), the initiative is the largest of its kind to test combinations of cancer drugs guided by tumor biology.
Clinical Trials Information for Patients and Caregivers
Types of cancer clinical trials include treatment, prevention, screening, and supportive and palliative care trials. Each type of trial is designed to answer different research questions and will help researchers learn things that will help people in the future.
Clinical trials to test new cancer treatments involve a series of steps, called phases. If a new treatment is successful in one phase, it will proceed to further testing in the next phase.
This phase 1/2 trial will test how well immunotherapy with tiragolumab and atezolizumab (Tecentriq) works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back or did not respond to therapy. Loss of the SMARCB1 and SMARCA4 genes is seen with some aggressive cancers that are often hard to treat. Doctors want to see if this treatment will help the body's immune system attack the cancer and interfere with the ability of tumor cells to grow and spread.
This study will examine the immune responses after COVID vaccination in people with cancer aged 6 months to 37 years. People with cancer often have suppressed or compromised immune systems, but vaccines work by bolstering the immune system to fight infection. Scientists want to see how the immune systems of young people with cancer respond to the COVID vaccine.
This phase 1 clinical trial will test a new type of T-cell therapy for people with KK-LC-1 positive cancers that have spread, come back, or not responded to treatment. KK-LC-1 is found in certain cancers, such as stomach, lung, breast, and cervical cancers. Doctors want to find the best dose of T-cell receptor gene therapy in people with these cancers.
